The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden

BACKGROUND: This paper presents the model and results to evaluate the use of teriparatide as a first-line treatment of severe postmenopausal osteoporosis (PMO) and Glucocorticoid-induced osteoporosis (GIOP). The study’s objective was to determine if teriparatide is cost effective against oral bispho...

Descripción completa

Detalles Bibliográficos
Autores principales: Murphy, Daniel R, Smolen, Lee J, Klein, Timothy M, Klein, Robert W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3545974/
https://www.ncbi.nlm.nih.gov/pubmed/23110626
http://dx.doi.org/10.1186/1471-2474-13-213

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3545974/
https://www.ncbi.nlm.nih.gov/pubmed/23110626
http://dx.doi.org/10.1186/1471-2474-13-213

Ejemplares similares